![Robert Emanuele](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Emanuele
Directeur/Membre du Conseil chez
ARTELO BIOSCIENCES, INC.
Fortune : 36 $ au 31/07/2026
Profil
Robert Martin Emanuele was the founder of Synthrx, Inc., founded in 2008, where the title held was President & Chief Executive Officer from 2008 to 2010.
Dr. Emanuele is also the founder of Visgenx, Inc...
Current positions include President & Chief Executive Officer at Liferaft Biosciences, Inc., and Independent Director at Artelo Biosciences, Inc. since 2017.
Former positions include Principal at EIDP, Inc.; Vice President-Research & Development at LadRx Corp.
from 1988 to 2002; Vice President-Pharmaceutical Strategy at DaVita, Inc. from 2010 to 2011; Senior Vice President-Business Development at Kémia, Inc. from 2006 to 2008; Chief Business Officer at Virobay, Inc.; Clinical Research Scientist at Dupont Critical Care, Inc.; VP-Corporate Development & Portfolio Management at Avanir Pharmaceuticals, Inc. from 2002 to 2006; Senior Vice President-Development at Mast Therapeutics, Inc. from 2011 to 2016; and Senior Vice President-Development at Savara, Inc. from 2011 to 2016.
Education includes undergraduate studies at Colorado State University, an MBA from The University of Colorado, and a doctorate from Stritch School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 17/07/2026 | 47 ( 0% ) | 36 $ | 31/07/2026 |
Postes actifs de Robert Emanuele
| Sociétés | Poste | Début |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Directeur/Membre du Conseil | 20/09/2017 |
Liferaft Biosciences, Inc. ,
 Liferaft Biosciences, Inc. , MiscellaneousMiscellaneous Operates as a non-classified establishment | Directeur Général | - |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Develops therapeutics to protect against the loss of sight from retinal disorders | Fondateur | - |
Anciens postes connus de Robert Emanuele
| Sociétés | Poste | Fin |
|---|---|---|
| SAVARA INC. | Corporate Officer/Principal | 28/10/2016 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for serious or life-threatening diseases with significant unmet needs | Corporate Officer/Principal | 01/10/2016 |
| DAVITA INC. | Corporate Officer/Principal | 01/04/2011 |
Synthrx, Inc.
 Synthrx, Inc. Miscellaneous Commercial ServicesCommercial Services Develops a purified form of a rheologic and antithrombotic agent | Directeur Général | 01/04/2010 |
Kémia, Inc.
 Kémia, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel small molecule therapeutics | Corporate Officer/Principal | 01/05/2008 |
Formation de Robert Emanuele
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
54
Relations au 1er degré
16
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 16 |
|---|---|
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries Manufactures and sells seed & crop protection products | Process Industries |
LadRx Corp.
 LadRx Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical research and development oncology company | Health Technology |
DaVita, Inc.
 DaVita, Inc. Medical/Nursing ServicesHealth Services Provides integrated dialysis services for patients suffering from chronic kidney failure | Health Services |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic products for the treatment of nervous system disorder | Health Technology |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for serious or life-threatening diseases with significant unmet needs | Health Technology |
Kémia, Inc.
Kémia, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel small molecule therapeutics | Health Technology |
Virobay, Inc.
 Virobay, Inc. Pharmaceuticals: MajorHealth Technology Develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases | Health Technology |
Artelo Biosciences, Inc.
 Artelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops endocannabinoid system modulating therapeutics | Health Technology |
Colorado State University
 Colorado State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Colorado
 The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dupont Critical Care, Inc. | |
Synthrx, Inc.
Synthrx, Inc. Miscellaneous Commercial ServicesCommercial Services Develops a purified form of a rheologic and antithrombotic agent | Commercial Services |
Stritch School of Medicine
 Stritch School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Savara, Inc.
 Savara, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals to treat respiratory diseases | Health Technology |
Liferaft Biosciences, Inc. ,
Liferaft Biosciences, Inc. , MiscellaneousMiscellaneous Operates as a non-classified establishment | Miscellaneous |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Develops therapeutics to protect against the loss of sight from retinal disorders | Health Technology |
